Cd27 v450

Manufactured by BioLegend

CD27-V450 is a fluorochrome-conjugated antibody produced by BioLegend. It is designed for the detection and analysis of CD27 expression on cells using flow cytometry.

Automatically generated - may contain errors

Lab products found in correlation

4 protocols using cd27 v450

Murine Mononuclear Cell Isolation and Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

Murine mononuclear cells from oHSV-infected brains were isolated as previously described (17 ). To obtain splenocytes, spleens were collected and homogenized through a 70 mm strainer. Erythrocytes were lysed using RBC lysis buffer (Biolegend, San Diego, CA). Cells isolated from either brains or spleens were treated with Fc Block antibody (anti CD16/32, BD Biosciences). Cells were stained with mouse-specific immune cell surface markers for 30 min at 4°C. The following anti-mouse antibodies were used at a dilution of 1:200: CD3-APC, NK1.1-PE, CD69-FITC, CD27-V450, CD11b-PE, CD45-APC, CD3-PE-Cy7, CD107-APC, CD11b-PErCP-Cy5.5, and IFN-γ-FITC (Biolegend, San Diego, CA). For CD107a staining, mononuclear cells were cultured in 10% RPMI media with monensin (eBioscience, San Diego, CA) for 4 h before cell-surface staining. For staining of IFN-γ, we treated the cells with Cytofix/Cytoperm (BD) following initial cell-surface staining and then performed intracellular staining.

Han J., Chen X., Chu J., Xu B., Meisen W.H., Chen L., Zhang L., Zhang J., He X., Wang Q.E., Chiocca E.A., Kaur B., Caligiuri M.A, & Yu J. (2015). TGF-β treatment enhances glioblastoma virotherapy by inhibiting the innate immune response. Cancer research, 75(24), 5273-5282.

+ Open protocol

+ Expand

Lymphocyte Subset Immunophenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunophenotyping of lymphocyte subpopulations was performed with the following antibodies: CD3-PerCP (clone: HIT3a, BioLegend), CD4-FITC (clone: RPA-T4, BioLegend), CD8-BV510 (clone: RPA-T8, BioLegend), CD45RA-PE-Cy7 (clone: HI100, BioLegend), CD27-APC (clone: M-T271, BioLegend), TCR aβ-PE (clone: IP2b, BioLegend), TCR γδ-BV421 (clone: B1, BioLegend), CD19-APC (clone: HIB19, BioLegend), CD27-V450 (clone: M-T271, BioLegend), IgD-AF488 (clone: IA6-2, BioLegend), CD24-PE (clone: ML5, BioLegend), and CD38-PerC P (clone: HIT2, BioLegend). The samples were acquired on a FACSCanto II flow cytometer, and the data were analyzed by FlowJo. All reference values were obtained from our recent study on peripheral lymphocyte phenotyping (17 (link)).

Huang Y., Fang S., Zeng T., Chen J., Yang L., Sun G., Dai R., An Y., Tang X., Dou Y., Zhao X, & Zhou L. (2022). Clinical and immunological characteristics of five patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome in China–expanding the atypical phenotypes. Frontiers in Immunology, 13, 972746.

+ Open protocol

+ Expand

Lymphocyte Immunophenotyping Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunophenotyping of lymphocyte subpopulations was performed with the following antibodies: CD3-PerCP (clone: HIT3a, BioLegend), CD4-FITC (clone: RPA-T4, BioLegend), CD8-BV510 (clone: RPA-T8, BioLegend), CD45RA-PE-Cy7 (clone: HI100, BioLegend), CD27-APC (clone: M-T271, BioLegend), TCR aβ-PE (clone: IP2b, BioLegend), TCR γδ-BV421 (clone: B1, BioLegend), CD19-APC (clone: HIB19, BioLegend), CD27-V450 (clone: M-T271, BioLegend), IgD-AF488 (clone: IA6-2, BioLegend), CD24-PE (clone: ML5, BioLegend), and CD38-PerCP (clone: HIT2, BioLegend). The samples were acquired on a FACSCanto II flow cytometer (BD Biosciences), and the data were analyzed using FlowJo. All reference values were obtained from our recent study on peripheral lymphocyte phenotyping.⁹ (link)

Yang L., Xue X., Zeng T., Chen X., Zhao Q., Tang X., Yang J., An Y, & Zhao X. (2020). Novel biallelic TRNT1 mutations lead to atypical SIFD and multiple immune defects. Genes & Diseases, 7(1), 128-137.

+ Open protocol

+ Expand

PBMC Flow Cytometric Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were used: CD3-PerCP (HIT3a), CD4-FITC (RPA-T4), CD8-BV510 ( RPA-T8), CD45RA-PE-Cy7 ( HI100), CD27-APC ( M-T271), TCR aβ-PE ( IP2b), TCR γδ-BV421 ( B1), CD19-APC ( HIB19), CD27-V450 ( M-T271), IgD-AF488 ( IA6-2), CD24-PE ( ML5), and CD38-PerCP ( HIT2), CD4-PE-Cy7 ( RPA-T4), CXCR5-BV421 ( J25ID4), CD25-APC ( MT271, ), CD127-PE ( A019D5, ), CCR6-PE ( G034E3, ), CD25-BV421 ( BC96, ), Helios-PerCP-cy5.5 ( 22F6, ), CD19-PerCP-Cy5.5 ( SJ25C1, ), CD27-PE-Cy7 ( MT271).
All were from Biolegend.
CD45RO-APC (UCHL 1), CD45RA-FITC (HI100), CXCR3-APC (1C6), and FOXP3-PE (PCH101), CD152-APC (BNI3), IgM-APC (G20-127) and IFN-γ-APC (4S.B3).
All were from BD Bioscicences. Th1 was defined as CD4 + CD45RA -CXCR5 -CXCR3 + CCR6 -, Th2 was defined as
The intracellular production of IFN-γ was investigated in PBMCs by flow cytometry. PBMCs (2 × 10 6 cells/ml) were either unstimulated or stimulated with PMA (50ng/ml) and Ionomycin (500ng/ml) for 5 hrs or BCG (MOI = 20) or 100 ng/ml BCG + IL-12 for 72 hrs, in 24-well plates. All the samples were treated with 1 μg/ml GolgiPlug (BD) for the last 2 or 6 hrs of culture.
The staining was performed according to manufacturers' guides. The samples were acquired on a FACSCanto II flow cytometer, and the data were analyzed using FlowJo.

Lv G., Sun G., Wu P., Du X.P., Zeng T., Wen W., Zhou L., An Y., Tang X., He T., Zhao X., & Du H. (2021). Novel mutations of TYK2 leading to divergent clinical phenotypes.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!